Mitchell Shirvan
CIK 1727789 · View on SEC EDGAR ↗
First SEC filing: Aug. 15, 2024 · Latest: June 8, 2026
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 26, 2026 | SLXNW | S | 22,818 | $1.36 | $31,032 | 27,889 Direct | -45.00% | Disposed | -99.0% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
SLXNW
Chief Scientific and Development Officer(5)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $190,286 | — | $1,043,699 | — | — | — | $67,505 | $1,301,490 |
| 2023 | $156,140 | — | — | — | — | — | $50,660 | $206,800 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.